Melatonin for recent central serous chorioretinopathy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether taking oral melatonin (a natural hormone) can help treat central serous chorioretinopathy, a condition where fluid builds up under the retina and blurs vision. It may be a good fit if you were recently diagnosed and haven't had certain eye procedures recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with central serous chorioretinopathy (a fluid leak under the retina) within the last 6 weeks.
- You must be at least 18 years old.
- You must agree to take part in the study.
- You cannot have had a vitrectomy (eye surgery to remove the gel inside the eye) at any time.
- You cannot have had laser surgery or anti-VEGF injections in the study eye in the past 3 months.
- You cannot be pregnant or nursing, or have other serious eye conditions in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a gentle laser treatment called micropulse laser for people with chronic central serous chorioretinopathy. It aims to help dry up the fluid under the retina that has not responded to standard medications for at least 6 months.
This study is testing whether mindfulness-based stress reduction can help people with central serous chorioretinopathy (CSCR), a condition causing fluid buildup under the retina. If you have active CSCR that started recently, you might be eligible.
This study looks at the link between gut bacteria and central serous chorioretinopathy (CSC), a condition where fluid builds up under the retina. It may help us understand why some people get CSC and find better ways to treat it.
This trial tests a low-energy “subthreshold” laser to treat long-lasting fluid under the retina from central serous chorioretinopathy (CSCR). It may help dry up the fluid and improve vision, compared with a sham (placebo) treatment.
This study measures blood flow in the eye in people with acute or chronic central serous chorioretinopathy (CSC). It uses eye scans and special imaging to better understand what’s happening and whether it may differ between short-term and long-term disease.
This trial studies rare diseases affecting the retina or choroid using detailed eye scans (OCT). It may help doctors better understand how these conditions look in the eye and how imaging findings relate to vision.
Hear when a new Central Serous Chorioretinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.